Integra LifeSciences (IART) to Release Earnings on Thursday
Integra LifeSciences (NASDAQ: IART) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th. Analysts are forecasting earnings per share of $0.80 and revenue of $429.62 million. The stock currently has a "Reduce" consensus rating from analysts, with shares opening at $11.99 and institutional ownership standing at approximately 84.78%.
Integra LifeSciences appoints new CTO and key executives
Integra LifeSciences Holdings Corporation has appointed Teshtar Elavia as Chief Technology Officer, Michael Hutchinson as Chief Legal Officer, and Kerri DiPietro as Chief Quality Officer in a strategic move to bolster its leadership. These appointments aim to strengthen the innovative capabilities and operational improvements of the medical technology company, especially as it faces profitability challenges and scrutiny over its TruDi Navigation System. Despite recent stock declines, analysts anticipate a return to profitability for Integra LifeSciences.
Integra LifeSciences Announces Key Executive Leadership Appointments
Integra LifeSciences Holdings Corporation has announced key executive leadership appointments, including Teshtar Elavia as corporate vice president and chief technology officer, Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer. The creation of the CTO role emphasizes Integra's commitment to innovation and product development, while the other appointments strengthen the company's legal, compliance, ESG, and global quality functions. These strategic hires aim to drive the company's transformation and long-term value.
New tech and quality chiefs signal Integra’s next growth push
Integra LifeSciences (Nasdaq: IART) announced three key executive appointments aimed at driving future growth and innovation. Teshtar Elavia was named the first Chief Technology Officer, Michael Hutchinson as Executive Vice President and Chief Legal Officer, and Kerri DiPietro as Corporate Vice President and Chief Quality Officer. These appointments are expected to enhance the company's R&D, legal, compliance, and quality systems, building on recent positive regulatory and market developments.
Integra LifeSciences Announces Key Executive Leadership Appointments
Integra LifeSciences has announced key executive leadership appointments, including Teshtar Elavia as Chief Technology Officer, Michael Hutchinson as Chief Legal Officer, and Kerri DiPietro as Chief Quality Officer. These appointments aim to strengthen the company's innovation engine, legal and compliance functions, and global quality management system, reflecting a commitment to strategic growth and transformation.
Global medical technology firm Integra LifeSciences sets Feb. 26 earnings call
Integra LifeSciences (NASDAQ: IART), a global medical technology company, will release its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, before market open. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss the results. Historically, similar announcements have led to mild stock price movements, with investors now keenly awaiting detailed financial disclosures.
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
Integra LifeSciences Holdings Corporation announced it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, before the market opens. Following the release, the management team will host a conference call at 8:30 a.m. ET, with a live webcast available on the company's investor relations website. Interested participants can register to receive dial-in details for the event.
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
Integra LifeSciences Holdings Corporation will release its fourth quarter and full year 2025 financial results on February 26, 2026, before the market opens. Management will host a conference call at 8:30 a.m. ET, and a live webcast will be available on the company's investor relations website. A webcast replay will also be accessible after the call.
Investors in Integra LifeSciences Holdings (NASDAQ:IART) have unfortunately lost 84% over the last five years
Integra LifeSciences Holdings (NASDAQ:IART) shareholders have experienced an 84% loss over the past five years, with a 59% drop in the last year alone. Despite a decline in share price, the company's revenue has increased by 2.6% annually over the same five-year period, suggesting a disconnect between market sentiment and underlying business performance. Recent insider buying indicates a potential positive outlook for the company's future, urging investors to consider fundamental metrics alongside stock performance.
FDA Alert Targets Integra LifeSciences' MediHoney Wound Products
The FDA has issued an alert regarding Integra LifeSciences' MediHoney Wound products, clarifying that they are not associated with MediWound. Integra LifeSciences operates in the medical device sector, focusing on regenerative therapy and neurosurgical applications. The company faces financial challenges, including negative margins and high leverage, despite strong institutional interest and recent insider buying.
Integra LifeSciences Holdings C (IART) Stock Analysis: Navigating a 23.41% Potential Upside Amidst Challenges
Integra LifeSciences Holdings C (IART) shows a potential upside of 23.41% despite mixed financial performance, including positive revenue growth but negative EPS and ROE. The company, which operates in the medical devices industry, has strong free cash flow and reinvests earnings, facing varied analyst sentiment with an average target price of $15.50. Technical indicators suggest an overbought condition, emphasizing the need for investors to monitor sector trends and company developments closely.
Integra LifeSciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Integra LifeSciences Holdings Corporation announced that its CEO, Mojdeh Poul, and CFO, Lea Knight, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. A live webcast of the presentation will be available on the company's investor relations website, providing broad access to their discussion on innovative treatment pathways in surgical, neurologic, and regenerative care. The company's participation highlights its standing in the medical technology sector and its commitment to engaging with investors.
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
Integra LifeSciences Holdings Corporation announced that CEO Mojdeh Poul and CFO Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. A live webcast of their presentation will be available on the company's investor relations website. Integra LifeSciences is a global medical technology company focused on surgical, neurologic, and regenerative care.
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
Integra LifeSciences Holdings Corporation announced that its CEO, Mojdeh Poul, and CFO, Lea Knight, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be available via live webcast on the company's investor relations website. Integra LifeSciences is a medical technology company focused on restoring patients' lives through innovative treatment pathways.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Rating of "Reduce" by Brokerages
Seven brokerages have issued a "Reduce" consensus rating for Integra LifeSciences Holdings Corporation (NASDAQ:IART), with an average 1-year price target of $15.00. This rating follows mixed quarterly results, where the company beat EPS expectations but missed revenue estimates and provided lower-than-analyst-expected Q4 and FY2025 guidance. Insider activity shows a director increasing their stake, while institutional investors hold a significant portion of the stock.
Is Integra LifeSciences (IART) Undervalued After Its Recent Share Price Rebound?
Integra LifeSciences (IART) has seen an 11% rebound recently, contrasting with a 40% year-down performance. Despite modest growth and losses, analysts suggest it is 15.5% undervalued with a fair value of $15.88, driven by strategic investments and cost optimization. The narrative emphasizes a potential future recovery and profit profile that could lead to double-digit upside.
Why Integra LifeSciences Holdings (IART) Is Up 17.7% After Medicare Expands Reimbursement for Skin Substitutes
Integra LifeSciences (IART) saw a 17.7% stock increase after Medicare expanded reimbursement for its skin substitute products, a move expected to boost patient access and commercial potential. This positive development supports the company's growth outlook, though ongoing operational risks from product recalls and manufacturing challenges remain concerns for investors. The company is projected to reach $1.9 billion in revenue and $90.9 million in earnings by 2028, with a fair value indicating a 21% upside.
Integra (NASDAQ: IART) gets FDA 510(k) for CUSA Clarity in cardiac surgery valve repair
Integra LifeSciences (Nasdaq:IART) has received FDA 510(k) clearance for its CUSA Clarity Ultrasonic Surgical Aspirator System for use in cardiac surgeries, specifically for debridement during valve replacement and repair. This expands the system's existing multi-specialty indications. The company plans to showcase CUSA Clarity at the AATS Mitral Valve Conclave in New York City on December 11–12, 2025.
Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference
Integra LifeSciences Holdings Corporation announced that CEO Mojdeh Poul and CFO Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025, at 10:30 a.m. ET. A live webcast of their presentation will be available on the company's investor relations website. The company aims to restore patients' lives through innovating treatment pathways and advancing surgical, neurologic, and regenerative care.
Integra LifeSciences (Nasdaq: IART) slated for Citi 2025 Global Healthcare Conference
Integra LifeSciences (Nasdaq: IART) announced that CEO Mojdeh Poul and CFO Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025, at 10:30 a.m. ET. A live webcast of their presentation will be available on the company's investor relations website under "Events & Presentations." The company, a global medical technology leader, aims to share its vision for restoring patients' lives through innovation in surgical, neurologic, and regenerative care.
Integra (Nasdaq: IART) Gains CMS 2026 Coverage for Skin Substitute Portfolio
Integra LifeSciences (Nasdaq: IART) announced that the Centers for Medicare & Medicaid Services (CMS) has included all of its skin substitutes in the CY 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules. This ruling establishes a uniform reimbursement rate across care settings for Integra's products, positively impacting multiple regulatory pathways including its FDA-approved Integra Dermal Regeneration Template. The company expects this to expand patient access to its wound reconstruction products beyond hospitals.
Integra LifeSciences Applauds CMS Ruling on Medicare Payment Schedule Benefiting Skin Substitute Products
Integra LifeSciences has applauded a recent CMS ruling for its 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which includes reimbursement for their dermal regenerative templates and other skin substitute products. This ruling ensures a uniform reimbursement rate across care settings, enhancing patient access to Integra's wound reconstruction products. The company believes this will reward innovation, quality, and improved patient outcomes, leading to expanded access to their diverse portfolio of cost-effective wound reconstruction solutions.
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
Integra LifeSciences Holdings Corporation commends CMS for its new Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules, which include all of Integra's skin substitute products. These policy advancements will allow Integra to expand access to its diverse portfolio of wound reconstruction solutions by establishing a uniform reimbursement rate across care settings. The company believes this will reward innovation, quality, and patient outcomes, aligning with Integra's leadership in these areas.
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
Integra LifeSciences commends the Centers for Medicare & Medicaid Services (CMS) for its Calendar Year 2026 rules that modernize payment structures to support broader access for Medicare beneficiaries to various skin substitutes. The new policies include all Integra dermal regenerative templates, decellularized dermal scaffolds, and amniotic tissue membranes, ensuring a uniform reimbursement rate across care settings. This development is expected to expand access to Integra's diverse portfolio of wound reconstruction solutions, which are backed by strong clinical evidence and innovative technology platforms.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Consensus Recommendation of "Reduce" from Brokerages
Integra LifeSciences Holdings Corporation (NASDAQ:IART) has received a consensus "Reduce" recommendation from eight brokerages, with analysts providing four "sell," two "hold," and two "buy" ratings and an average 12-month price target of $15.83. The company's stock jumped approximately 9% to $12.04 after reporting Q3 EPS of $0.54, beating consensus estimates, and providing Q4/FY2025 guidance. Insider activity shows Director Jeffrey A. Graves recently acquired 9,000 shares, increasing his stake by 28%.
FDA Grants 510(k) Clearance to Ultrasonic Surgical Aspirator System for Cardiac Surgeries
Integra LifeSciences Holdings Corp. has received FDA 510(k) clearance for its CUSA Clarity Ultrasonic Surgical Aspirator System for use in cardiac surgeries, specifically for debridement in procedures like valve replacement. This expands the system's indications beyond neurosurgery, plastic surgery, and other surgical fields. The company plans to showcase the CUSA Clarity at the American Association for Thoracic Surgeon Mitral Valve Conclave.
Integra LifeSciences stock jumps after FDA clearance for cardiac surgery device
Integra LifeSciences Holdings Corporation (NASDAQ:IART) saw its stock rise 5.4% after receiving FDA 510(k) clearance for its CUSA® Clarity Ultrasonic Surgical Aspirator System for cardiac surgeries. This approval allows the device to be used in cardiac procedures, expanding its applications beyond existing specialties. The company plans to showcase the system at the American Association for Thoracic Surgeon Mitral Valve Conclave in December, indicating potential new revenue streams in the cardiac surgery market.
Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries
Integra LifeSciences Holdings Corporation has announced FDA 510(k) clearance for its CUSA® Clarity Ultrasonic Surgical Aspirator System for use in cardiac surgeries, including valve replacement and repair. This expands the system's indications beyond other surgical fields. The company plans to showcase the CUSA Clarity system at an upcoming cardiology conference.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q3 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation reported Q3 2025 earnings, beating EPS expectations with $0.54 but missing revenue guidance due to supply interruptions. The company discussed progress on its Compliance Master Plan, operational excellence, and reintroduction of PriMatrix and Durepair, while also providing updated full-year 2025 financial guidance. Executives addressed analyst questions regarding Q4 guidance, 2026 growth prospects, private label business challenges, MediHoney remediation, and the strategic portfolio prioritization.
Integra LifeSciences (IART): Deep Valuation Discount Tests Profitability Timeline, Spotlights Risk-Reward Divide
Integra LifeSciences (IART) is currently unprofitable, with losses widening, but is projected to return to profitability within three years due to an expected 166.84% annual earnings growth. The company faces challenges including compressed margins, high net debt, and operational disruptions, but its shares trade at a significant discount to its DCF fair value, suggesting potential upside if operational improvements materialize. Investors are closely monitoring margin recovery and debt management efforts to gauge the company's financial durability.
Integra LifeSciences beats on earnings despite revenue miss
Integra LifeSciences Holdings Corporation (NASDAQ:IART) reported strong third-quarter earnings of $0.54 per share, surpassing analyst estimates, but missed revenue targets with $402.1 million. Despite a 5.6% revenue increase year-over-year, the company lowered its fourth-quarter and full-year 2025 revenue guidance due to supply interruptions. Integra LifeSciences' shares fell 2.79% in pre-market trading following the mixed results and reduced outlook.
Integra LifeSciences stock hits 52-week low at 11.05 USD
Integra LifeSciences Holdings (IART) stock has hit a new 52-week low of $11.05, representing a 38.75% decline over the past year. The company, burdened by over $2 billion in total debt and a market cap of $868.71 million, is not currently profitable but analysts predict an EPS of $2.17 for FY2025. Despite revenue shortfalls in Q3 2025, the stock is considered significantly undervalued by InvestingPro, indicating potential for future recovery.
Earnings call transcript: Integra LifeSciences Q3 2025 beats EPS expectations
Integra LifeSciences (IART) reported Q3 2025 earnings, surpassing EPS expectations by 25.58% with an adjusted EPS of $0.54, but missing revenue forecasts at $402 million against an anticipated $414.23 million. The company's stock saw a slight pre-market increase of 0.06% despite the mixed results. Key initiatives include strengthening quality systems, improving operational excellence, and relaunching products like Primatrix® and DuraPair® ahead of schedule.
Integra LifeSciences Q3 Loss Narrows; Cuts FY25 Revenue Guidance; Stock Up
Integra LifeSciences Holdings Corp. (IART) reported a narrower loss for the third quarter of 2025 compared to the previous year, driven by higher revenues. The company, however, lowered its revenue guidance for the full fiscal year 2025, while providing projections for the fourth quarter. Despite the reduced outlook, the stock was trading up in pre-market activity due to the better-than-expected earnings per share.
Integra LifeSciences Slashes FY25 Outlook - Update
Integra LifeSciences Holdings Corp. (IART) has lowered its adjusted earnings and revenue guidance for the full-year 2025. The medical technology company now projects adjusted earnings between $2.19 and $2.24 per share on revenues of $1.62 billion to $1.64 billion, reflecting an organic revenue decline. This revised outlook is below previous expectations and analyst consensus.
Integra LifeSciences (NASDAQ:IART) Misses Q3 Sales Expectations
Integra LifeSciences (NASDAQ:IART) reported Q3 CY2025 results, missing Wall Street's revenue expectations but exceeding non-GAAP profit estimates. Sales increased by 5.6% year-on-year to $402.1 million, but the company's Q4 revenue guidance of $430 million fell short of analysts' estimates. Despite strong profitability and cash flow driven by cost management, the company's stock traded down 4.4% immediately after the report due to the revenue miss and conservative guidance.
Integra LifeSciences Reports Third Quarter 2025 Financial Results
Integra LifeSciences Holdings Corporation reported third-quarter 2025 financial results, with revenues of $402.1 million, an increase of 5.6% reported and 5.0% organic. The company achieved adjusted EPS of $0.54 and is making progress on its supply chain and quality system improvements, including the ahead-of-schedule relaunch of PriMatrix® and Durepair®. Integra LifeSciences also revised its full-year 2025 guidance to reflect third-quarter performance and updated fourth-quarter assumptions.
Integra LifeSciences Reports Third Quarter 2025 Financial Results
Integra LifeSciences (Nasdaq: IART) reported its third-quarter 2025 financial results, with revenues reaching $402.1 million, a 5.6% increase on a reported basis. The company achieved adjusted earnings per diluted share of $0.54, exceeding $0.41 in the prior year, despite supply interruptions impacting revenue. Integra is implementing a comprehensive plan to strengthen its supply chain and quality management system, and revised its full-year 2025 revenue guidance to $1.620 billion to $1.640 billion.
Does Integra LifeSciences Share Rebound Signal a New Growth Phase in 2025?
Integra LifeSciences (IART) has experienced a significant share rebound following a challenging year, sparking investor interest in a potential turnaround. The stock shows indicators of undervaluation based on Simply Wall St's valuation score and discounted cash flow analysis, suggesting a deep discount relative to its underlying cash flow potential. Its Price-to-Sales ratio is also well below industry averages, further indicating potential undervaluation when accounting for growth and risk factors through Simply Wall St's "Fair Ratio" methodology.
Why Integra LifeSciences (IART) Shares Are Trading Lower Today
Integra LifeSciences (IART) shares fell after Truist maintained a "Hold" rating, citing expected "healthy" Q3 revenue in the medical technology sector but also anticipating stock volatility. The company is set to release its Q3 financial results on October 30. Despite the drop, IART's shares are notably volatile, and the medical device company is currently down 38.4% year-to-date.
Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025 - Yahoo Finance
Integra LifeSciences announced it will host a conference call on October 30, 2025, to discuss its third quarter 2025 financial results. The call will be accessible via a live webcast on the Investors section of the company's website. Integra LifeSciences is a medical technology company focused on restoring patients' lives through surgical, neurologic, and regenerative care.
Q3 2025 Results — Integra LifeSciences to Release Oct. 30; Webcast and Conference Call - Stock Titan
Integra LifeSciences (Nasdaq: IART) will release its third-quarter 2025 financial results on Thursday, October 30, 2025, before the market opens. Following the release, the company will host a conference call at 8:30 a.m. ET, and a live webcast will be available on its Investors website. Investors can register to receive dial-in details and an individual PIN for the conference call, with a replay also available on the website.
Wealth Enhancement Advisory Services LLC Purchases 1,927 Shares of Integra LifeSciences Holdings Corporation $IART - Defense World
Wealth Enhancement Advisory Services LLC recently increased its stake in Integra LifeSciences Holdings Corporation (IART) by purchasing an additional 1,927 shares. Several other institutional investors also adjusted their holdings in IART this quarter. The article notes a recent 5.8% drop in Integra LifeSciences' stock and provides a company profile outlining its product offerings.
Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer
Integra LifeSciences Holdings Corporation has appointed Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner, a board-certified endovascular neurosurgeon with over 20 years of experience, will oversee worldwide medical affairs and clinical development activities. His expertise is expected to significantly contribute to strengthening Integra's focus on building robust clinical evidence and delivering innovative solutions.
Medical Tech Leader Integra LifeSciences Sets Dual Conference Appearances in September 2025
Integra LifeSciences (NASDAQ:IART) announced that its leadership, CEO Mojdeh Poul and CFO Lea Knight, will present at two healthcare investor conferences in September 2025. They will attend the Wells Fargo Healthcare Conference on September 3rd and the Morgan Stanley Healthcare Conference on September 10th. Investors can access live webcasts of these presentations through the company's investor relations website.
Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
Integra LifeSciences (IART) reported strong Q2 earnings of $0.45 per share, surpassing the Zacks Consensus Estimate of $0.43, and revenues of $415.61 million, beating estimates by 5.05%. Despite this outperformance, the company's shares have significantly underperformed the S&P 500 year-to-date. The stock currently holds a Zacks Rank #3 (Hold), indicating an expected in-line performance with the market in the near future.
Integra LifeSciences Reports Second Quarter 2025 Financial Results
Integra LifeSciences Holdings Corporation reported its Q2 2025 financial results, with revenues of $415.6 million and adjusted EPS of $0.45, exceeding guidance. The company recorded a GAAP net loss due to a significant goodwill impairment charge but highlighted strong organic growth in neurosurgery and tissue technologies. Integra LifeSciences also updated its full-year revenue guidance and reaffirmed its adjusted EPS outlook, emphasizing progress in compliance and operational efficiency.
Is Integra LifeSciences Holdings (NASDAQ:IART) Using Too Much Debt?
Integra LifeSciences Holdings (NASDAQ:IART) carries US$1.85 billion in debt, with net debt at US$1.57 billion. The company's total liabilities exceed its cash and short-term receivables by US$2.00 billion, and its debt is 4.9 times its EBITDA. Given a 28% decline in EBIT over the last year and free cash flow covering only 34% of EBIT, the article concludes that Integra LifeSciences Holdings has too much debt.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
Pomerantz LLP is investigating potential securities fraud claims against Integra LifeSciences Holdings Corporation (IART) on behalf of its investors. This investigation follows Integra's Q1 2025 financial results, which reported significantly missed earnings and revenue guidance, leading to a substantial drop in its stock price. Investors are encouraged to contact the law firm for more information regarding joining a potential class action.
integra lifesciences amends credit agreement to adjust leverage ratio
Integra LifeSciences announced an amendment to its credit agreement, adjusting the company's leverage ratio effective June 6, 2025. This amendment, which modifies the maximum permitted consolidated total leverage ratio and introduces a Covenant Relief Period, aims to manage financial obligations while maintaining strategic flexibility. The company also reported Q1 2025 earnings which missed forecasts, leading JMP analysts to reduce their price target to $25.
